Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
Journal of Dermatological Science Feb 10, 2018
Wang FP, et al. - In case of atopic dermatitis (AD), the overall efficacy of dupilumab treatment was gauged by the researchers. Dupilumab resulted in clinically relevant improvements in the signs and symptoms of the AD, displaying an acceptable safety profile. Similar benefits were noted by the dose regimens of 300 mg QW and Q2W.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
